We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our products are promoted to veterinarians and livestock producers by our sales organization which includes sales representatives and technical and veterinary operations specialists, and then sold directly by us or through distributors, retailers and e-commerce outlets. The depth of our product portfolio enables us to address the varying needs of customers in different species and geographies. Many of our top selling product lines are distributed

across both of our operating segments, leveraging our research and development (R&D) operations and manufacturing and supply chain network.

Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to a single product in all brands, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both livestock and companion animals across each of our major product categories.

In the fourth quarter of 2019, the company modified the list of major product categories to include a category for dermatology products, which was previously included within other pharmaceutical products. The prior period presentation has been revised to reflect the new product categories.

•vaccines: biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response;

•animal health diagnostics: portable blood and urine analysis systems and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits and blood glucose monitors.

Our remaining revenue is derived from other non-pharmaceutical product categories, such as nutritionals and agribusiness, as well as products and services in smaller but fast growing areas, including biodevices, genetic tests and precision livestock farming.

Our livestock products primarily help prevent or treat diseases and conditions to enable the cost-effective production of safe, high-quality animal protein. Human population growth and increasing standards of living are important long-term growth drivers for our livestock products in three major ways. First, population growth and increasing standards of living drive increased demand for improved nutrition, particularly animal protein. Second, population growth leads to increased natural resource constraints driving a need for enhanced productivity. Finally, as standards of living improve, there is increased focus on food quality and safety.

Our companion animal products help extend and improve the quality of life for pets; increase convenience and compliance for pet owners; and help veterinarians improve the quality of their care and the efficiency of their businesses. Growth in the companion animal medicines, vaccines and diagnostics sector is driven by economic development, related increases in disposable income and increases in pet ownership and spending on pet care. Companion animals are also living longer, receiving increased medical treatment and benefiting from advances in animal health medicines and vaccines.


	Three Months Ended						Six Months Ended
	June 30,						June 30,
(MILLIONS OF DOLLARS)	2020		2019		2020		2019
United States	$	823	$	780	$	1,609	$	1,498
Australia	51		49		94		97
Brazil	56		74		119		134
Canada	54		54		94		95
Chile	25		22		48		42
China	66		56		132		116
France	24		27		53		59
Germany	40		39		74		76
Italy	14		28		35		56
Japan	53		41		94		78
Mexico	26		30		58		58
Spain	24		30		52		57
United Kingdom	26		42		81		99
Other developed markets	90		88		177		172
Other emerging markets	159		162		325		321
	1,531		1,522		3,045		2,958
Contract manufacturing & human health	17		25		37		44
Total Revenue	$	1,548	$	1,547	$	3,082	$	3,002


	Three Months Ended						Six Months Ended
	June 30,						June 30,
(MILLIONS OF DOLLARS)	2020		2019		2020		2019
U.S.
Companion animal	$	594	$	500	$	1,093	$	945
Livestock	229		280		516		553
	823		780		1,609		1,498
International
Companion animal	288		298		586		582
Livestock	420		444		850		878
	708		742		1,436		1,460
Contract manufacturing & human health	17		25		37		44
Total Revenue	$	1,548	$	1,547	$	3,082	$	3,002


	Three Months Ended						Six Months Ended
	June 30,						June 30,
(MILLIONS OF DOLLARS)	2020		2019		2020		2019
Companion Animal:
Dogs and Cats	$	831	$	754	$	1,577	$	1,442
Horses	51		44		102		85
	882		798		1,679		1,527
Livestock:
Cattle	320		379		690		759
Swine	146		158		303		307
Poultry	135		143		283		282
Fish	30		25		56		48
Sheep and other	18		19		34		35
	649		724		1,366		1,431
Contract manufacturing & human health	17		25		37		44
Total Revenue	$	1,548	$	1,547	$	3,082	$	3,002


	Three Months Ended						Six Months Ended
	June 30,						June 30,
(MILLIONS OF DOLLARS)	2020		2019		2020		2019
Vaccines	$	336	$	370	$	685	$	728
Parasiticides	307		266		562		497
Anti-infectives	241		293		521		579
Dermatology	227		185		424		344
Other pharmaceuticals	192		187		389		377
Medicated feed additives	109		115		234		227
Animal health diagnostics	69		65		129		125
Other non-pharmaceuticals	50		41		101		81
	1,531		1,522		3,045		2,958
Contract manufacturing & human health	17		25		37		44
Total Revenue	$	1,548	$	1,547	$	3,082	$	3,002

Contract liabilities reflected within Other current liabilities as of December 31, 2019 and December 31, 2018, and subsequently recognized as revenue during the first six months of 2020 and 2019 were approximately $5 million and $4 million, respectively. Contract liabilities as of June 30, 2020 and December 31, 2019 were approximately $10 million and $11 million, respectively.